Journal article
Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
The Lancet (British edition), v 399(10320), pp 143-151
01 Jan 2022
PMID: 34800427
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Background Aspirin has been proposed as a treatment for COVID-19 on the basis of its anti-thrombotic properties. We aimed to evaluate the efficacy and safety of aspirin in patients admitted to hospital with COVID-19.
Methods In this randomised, controlled, open-label, platform trial, several possible treatments were compared with usual care in patients hospitalised with COVID-19. The trial took place at 177 hospitals in the UK, two hospitals in Indonesia, and two hospitals in Nepal. Eligible and consenting adults were randomly allocated in a 1:1 ratio to either usual standard of care plus 150 mg aspirin once per day until discharge or usual standard of care alone using web-based simple (unstratified) randomisation with allocation concealment. The primary outcome was 28 day mortality. All analyses were done by intention to treat. The trial is registered with ISRCTN (50189673) and ClinicalTrials.gov (NCT04381936).
Findings Between Nov 1, 2020, and March 21, 2021, 14 892 (66%) of 22560 patients enrolled into the RECOVERY trial were eligible to be randomly allocated to aspirin. 7351 patients were randomly allocated (1:1) to receive aspirin and 7541 patients to receive usual care alone. Overall, 1222 (17%) of 7351 patients allocated to aspirin and 1299 (17%) of 7541 patients allocated to usual care died within 28 days (rate ratio 0.96, 95% CI 0.89-1.04; p=0.35). Consistent results were seen in all prespecified subgroups of patients. Patients allocated to aspirin had a slightly shorter duration of hospitalisation (median 8 days, IQR 5 to >28, vs 9 days, IQR 5 to >28) and a higher proportion were discharged from hospital alive within 28 days (75% vs 74%; rate ratio 1.06, 95% CI 1.02-1.10; p=0.0062). Among patients not on invasive mechanical ventilation at baseline, there was no significant difference in the proportion meeting the composite endpoint of invasive mechanical ventilation or death (21% vs 22%; risk ratio 0.96, 95% CI 0.90-1.03; 1:0. 23). Aspirin use was associated with a reduction in thrombotic events (4.6% vs 5.3%; absolute reduction 0.6%, SE 0.4%) and an increase in major bleeding events (1.6% vs 1.0%; absolute increase 0.6%, SE 0.2%).
Interpretation In patients hospitalised with COVID-19, aspirin was not associated with reductions in 28 day mortality or in the risk of progressing to invasive mechanical ventilation or death, but was associated with a small increase in the rate of being discharged alive within 28 days. Copyright (C) 2021 The Author(s). Published by Elsevier Ltd.
Metrics
Details
- Title
- Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
- Creators
- Peter W. Horby - RECOVERY Cent Coordinating Off, Oxford OX3 7LF, EnglandGuilherme Pessoa-AmorimNatalie StaplinJonathan R. EmbersonMark CampbellEnti SpataLeon PetoNigel J. BrunskillSimon TiberiVictor ChewThomas BrownHasan TahirBeate EbertDavid ChadwickTony WhitehouseRahuldeb SarkarClive GrahamJ. Kenneth BaillieBuddha BasnyatMaya H. BuchLucy C. ChappellJeremy DaySaul N. FaustRaph L. HamersThomas JakiEdmund JuszczakKatie JefferyWei Shen LimAlan MontgomeryAndrew MumfordKathryn RowanGuy ThwaitesMarion MafhamRichard HaynesMartin J. Landray - RECOVERY Cent Coordinating Off, Oxford OX3 7LF, EnglandRECOVERY Collaborative GrpLindsay A Steele - School of Biomedical Engineering, Science, and Health Systems (1997-)
- Publication Details
- The Lancet (British edition), v 399(10320), pp 143-151
- Publisher
- Elsevier
- Number of pages
- 9
- Grant note
- UK Research and Innovation (Medical Research Council) Wellcome Trust National Institute of Health Research; National Institute for Health Research (NIHR)
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- School of Biomedical Engineering, Science, and Health Systems; Drexel University
- Web of Science ID
- WOS:000740652500020
- Scopus ID
- 2-s2.0-85122294690
- Other Identifier
- 991019356496504721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
Highly Cited Paper
- Web of Science research areas
- Medicine, General & Internal